



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

	C mpl te if Known	12 EB
Application Number	09/868,276	5 1
Filing Date	June 15, 2001	D A
First Named Inventor	Allen, Darin A., et. al.	6
Art Unit	1624	8 8
Examiner Name	S. Patel	29
Attorney Docket Number	015058-003210US	8

			U.S. PATENT D	OCUMENTS		
		Document Number				
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-				
	AB	US-				
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-			·	
	Al	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				
	AN	US-			<u> </u>	
	AO	US-				
	AP	US-				
	AQ	US-				
	AR	US-				
	AS	US-				
	AT	US-				

			FOREIGN PA	TENT DOCUME	NTS		
Examiner Initials No. No. 1		Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear]
	Country Code ³	Number ⁴ Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Document		T⁵		
00	AU	JP	02306916				
not.	AV	WO	9822619	05-28-1998			
only	AW	WO	9926933	06-03-1999			
1	AX	wo	9926941	06-03-1999			<u> </u>
100	AY	HU	192152	04-30-1984			
4	AZ						
	ВА						\Box
	ВВ						

	())) () ()			
Examiner Signature	mal h h total	Date Considered	613/a2	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

WC 9051667 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons	are required to respond to a collection of	of information unless it contains a valid OMB	control duff
Substitute for form 1449B/PTO		Complete if Known	ï
	Application Number	09/868,276	ìi
INFORMATION DISCLOSURE	Filing Date	June 15, 2001	~
STATEMENT BY APPLICANT	First Named Inventor	Allen, Darin A., et. al.	끘
	Art Unit	1624	

(use as many sheets as necessary) **Examiner Name**

S. Patel 015058-003210US Attorney Docket Number of Sheet

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
00	вс	TIDWELL R.R. <i>ET AL</i> . "Diarylamidine derivatives with one or both of th earyl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases" <i>J. Med. Chem.</i> 1978 , <i>21</i> (7), 613-623.	
Ro	BD	NISHI T. ET AL. "Preparation of benzothiazoles and benzimidazoles as blood platelet aggregation inhibitors" CHEMICAL ABSTRACTS 1991, 114(21), 832.	
06	BE	IWANOWICZ E.J. ET AL. "Derivatives of 5-amidine indole as inhibitors of thrombin catalytic activity" Bioorganic & Medicinal Chemistry Letters 1996, 6(12), 1339-1344.	
D	BF .	KATZ B.A. ET AL. "Design of potent selective zinc-mediated serine protease inhibitors" Nature 1998, 391, 608-612.	
	BG		
	вн		
	Ві		
	ВЈ		
	вк		
	BL		
	ВМ		

Examiner Signature	hidhlystotos	Date Considered	6/18/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. WC 9051667 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.